Qiagen Building Sample-Prep Tech for Colorectal Cancer Test Under Epigenomics Option

The deal makes Qiagen the latest company to work with Epigenomics to craft a test based on mSEPT9. Qiagen hopes to distinguish itself, however, by developing a new front-end sample-prep technology that will optimize the test for use on its QIAsymphony automated modular testing platform.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.